In another study by Kang et al., in 44 patients with stage III-IV NSCLC, a decrease in plasma IL-8 three months following anti-PD-1 combined with hypo-fractionated radiotherapy was reported in patients with disease remission or stable disease, while patients with PD had increases in IL-8; lower levels of IL-8 after treatment were also associated with prolonged OS (p = 0.0058) [42]. Here, CXCL8 is linked to non-small cell lung carcinoma.